- Curia is expanding its sterile drug product facility in Glasgow, UK, with completion expected by early 2027.
- The company has enhanced its cell line development platform, achieving up to six-fold higher titers.
Curia has announced progress on the expansion of its sterile drug product facility in Glasgow, UK, alongside enhancements to its cell line development platform, as part of its broader CDMO and contract manufacturing strategy.
The Glasgow site, which has over 25 years of experience in formulation, lyophilization, and sterile fill-finish operations, is being upgraded with an Annex 1 compliant isolator-based vial filling line and lyophilizer. The expansion is expected to be completed by early 2027 and will enable batch sizes of up to 20,000 vials, supporting small-scale commercial manufacturing.
The company stated that it has secured key equipment to maintain project timelines and does not anticipate disruption to ongoing operations during construction. The expansion follows ongoing investments in Curia’s commercial drug product facility in Albuquerque, New Mexico.
In parallel, Curia has enhanced its biologics capabilities at its Hopkinton, Massachusetts site through improvements to its cell line development platform. The updated system incorporates semi-targeted integration technology, resulting in six-fold higher titers compared to random integration methods.
“Our biologics division has always had end-to-end capabilities, and we are excited to offer a cell line that makes it more cost-efficient and faster to advance partners through early-stage clinical manufacturing.”
Jamie Grabowski, President, Research & Development
